Background/Objectives: To investigate the feasibility of Fabuless (previously called Olibra and Reducal) as a food ingredient for food intake and appetite reduction, by assessing the effects of food processing on efficacy. Subjects/Methods: In total, 24 healthy volunteers (16 female, 8 male; age: 18-43 years; body mass index: 18-37 kg/m 2 ) took part in a randomized, placebo-controlled, double-blinded, cross-over trial. Yoghurt-based meal replacement drinks (containing processed or unprocessed Fabuless, or a control fat) were followed by an ad libitum lunch and evening meal (dinner). Key outcome measures were energy intake and self-reported appetite ratings. Results: Compared with control, only unprocessed Fabuless reduced subsequent energy intake, although only during dinner (Po0.01; control, processed and unprocessed: 4.3, 3.9 and 4.2 MJ, respectively) and not during lunch (3.6, 3.7 and 3.6 MJ). Self-reported appetite scores did not differ between treatments. Conclusions: Although modest effects of unprocessed Fabuless were seen on food intake, but not on appetite, the ingredient was not robust to common food-manufacturing processes (thermal and shear processing). Claims on reduced food intake and appetite relating to this ingredient in food products are, therefore, only valid if functionality has been demonstrated after all relevant processing and storage steps.
Introduction
Fabuless* is a 42% fat emulsion formulated from palm oil and oat oil fractions, used as a food ingredient and claimed to reduce appetite and food intake. It is produced by Lipid Technologies Provider AB (LTP, Karlshamn, Sweden) and marketed for satiety benefits in food applications by DSM (Koninklijke DSM N.V., Heerlen, the Netherlands). The initial published research, all of which was performed in one laboratory by the same research group, reported significant decreases in energy and macronutrient intakes 4-8 h posttreatment when Fabuless, compared with a control fat, was added to yoghurt (Burns et al., 2000 (Burns et al., , 2001 , and that these effects were dose-dependent (Burns et al., 2002) . However, no subsequent studies have replicated these initial results. Indeed, a later study by the same group failed to replicate these positive findings (Logan et al., 2006) after either acute or chronic (3-week) intakes. Similarly, in a different laboratory, Diepvens et al. (2008) did not find any overall effects of Fabuless on food intake. As Fabuless is a complex structured emulsion, rather than a single chemical entity, it is possible that unspecified differences in the material or its handling could contribute toward inconsistencies in its reported efficacy.
In the studies that showed a significant inhibitory effect of Fabuless on food consumption (Burns et al., 2000 (Burns et al., , 2001 (Burns et al., , 2002 , it is not clear exactly how the active ingredient was added to the test yoghurts and the amount of processing (that is, significant mixing or heating) involved. The physical structure of the Fabuless emulsion is thought to be critical for its putative functionality within the gastrointestinal tract and it is not clear to what extent normal food processing may affect its efficacy. It is, therefore, also not clear if research carried out under one set of processing conditions can support claims where in reality, this ingredient undergoes a different set of conditions (or for that matter, potential changes during product shelf-life). Commercial food-manufacturing processes, which guarantee food safety, expose ingredients to shear stress (through mixing and homogenization) and raised temperatures (through pasteurization and so on). The goal of this study was to assess the feasibility of Fabuless as a hunger control ingredient in yoghurt-based meal replacement beverages and to establish the impact of specific production processes on its ability to reduce appetite and food intake.
Materials and methods

Study design
In total, 24 healthy volunteers were recruited from the Bristol University campus and its surrounding area through an existing participant database and through posters displayed in various departments of Bristol University. Exclusion criteria were as follows: currently dieting to lose weight; getting up and/or having breakfast after 0900 hours regularly; skipping breakfast, lunch or dinner regularly; being a self-defined 'picky' eater; having simultaneous involvement in other intervention studies, being a smoker, taking any prescribed medication; in pregnancy or breastfeeding. In order to minimize expectancy effects, the exact objectives of the study were concealed and the study was, therefore, presented as investigating the 'Effects of a new yoghurt product on mood and hunger'. In addition, subjects were excluded if they scored high for cognitive restraint according to the Dutch eating behaviour questionnaire (DEBQ; van Strien et al., 1986a) . The exact exclusion criteria used were (van Strien, personal communication, updated from van Strien et al., 1986b) The study protocol was approved by the relevant Human Research Ethics Committee at the University of Bristol and participants provided written informed consent at the end of the practice/familiarization visit. At the very end of the study, they received a full written debriefing including an explanation of the purpose of the study. Participants were assigned to the three conditions according to a balanced, randomized, placebo-controlled, and double-blinded cross-over design. The study was conducted over two periods of 2 weeks; however, due to the limited shelf-life of the test product, participants 1-12 were tested in weeks 1-2 and participants 13-24 were tested in weeks 3-4. The design of the study balanced treatments within these cohorts.
Before testing commenced, subjects attended an introduction/familiarization session in the laboratory, where they practised the main visual-analogue scale (VAS) questionnaire of the study (see below) several times and completed the DEBQ. Height and weight were measured and they were given a 'Drink, Activity & Evening Snack Diary' for additional data collection, with extensive instructions.
Subsequently, participants returned for their three testing days after fasting from 2000 hours the previous evening. On test days, participants consumed their treatment (breakfast as meal replacement drink) at 0900 hours, their ad lib lunch at 1300 hours and their ad lib dinner at 1700 hours. Before each ad lib meal, they were reminded to 'eat until you feel comfortably full-no more and no less'. The meals selected were intended to be of average liking (not disliked, so that participants would eat much less than normal and possibly compensate with larger snacks in the evenings, and not overly liked, so that participants would eat much more than normal). This was explained, as was the food they would receive, and they were asked to consider not taking part if they felt the meals were not moderately liked. Additionally, they were asked to keep an activity and drinks diary on the first testing day, which they had to follow as closely as possible on each of the subsequent testing days with the explicitly explained aim of keeping all testing days as identical as possible and thereby keeping inter-day variability to an absolute minimum. Exercise was not allowed on a testing day until later that evening, nor were additional evening meals. Participants were asked not to eat anything else during the testing day until the evenings of the testing days, when snacks and alcoholic drinks were allowed, although these were recorded using the same diary. Also, participants were instructed to bring some light reading material to entertain themselves during in-laboratory waiting times, and magazines were provided. Each participant occupied an individual testing booth, whereby distraction was kept to a minimum: they were visually separated; talking among participants was prohibited; and mobile phones were handed to the experimenter to avoid any further distractions. Participants were allowed to leave when all present had finished eating their test meal, although for lunch and dinner subjects could leave only after the first post-meal questionnaires (30 min after the start of the meal; see below) were completed.
At baseline and every 30 min post-treatment until after dinner, VAS questionnaires were filled out using a preprogrammed Palm Zire 21 handheld Personal Digital Assistant (PDA). VAS questionnaires recorded appetite and mood-related feelings (see below). In total, five of these questionnaires were followed by a 4-point 'physical symptoms' questionnaire, including one immediately pre-meal, one at 1100 hours and one at 1500 hours. Additionally, a palatability questionnaire was completed for each of the treatments.
A schematic representation of the various activities can be found in Figure 1 .
Test foods Breakfast (treatment).
The three treatment yoghurt-based meal replacement drinks or 'test drinks' (325 ml each) contained either 12.5 g Fabuless (5 g fat; added during manufacture, thus 'processed'), 12.5 g Fabuless (5 g fat; added at the end of manufacture, thus 'unprocessed') or 5 g control fat (milk fat þ corn oil). Additions of Fabuless at or below 12.5 g have been reported to substantially reduce food intake in the original efficacy studies (Burns et al., 2000 (Burns et al., , 2001 (Burns et al., , 2002 . In the 'processed' condition, Fabuless was mixed with all other ingredients at the start of the production process. Subsequent processing steps involved pre-heating to 72 1C, homogenization at 65 1C, pasteurization at 92 1C for 5 min, cooling to 42 1C for 5 h, pH adjustment to 4.6, and final homogenization with fruit-based ingredients. In the 'unprocessed' condition, Fabuless was added after this final step with minimal mixing, then manually filled into aseptic containers for storage at o8 1C to ensure a shelf-life of 14 days. The product description of the test drinks was 'A fresh raspberry yoghurt beverage containing vitamins and minerals, with sugars and sweeteners' and contained the following ingredients: live yoghurt (milk, whey, milk protein); raspberry puree; sucrose; glucose; oligofructose (fibre); vegetable oils; minerals; vitamins; stabilizer (pectin); sweeteners (aspartame, acesulfame K); flavouring; colour (carmine). Serving size for all three treatments was 325 ml (336 g). Energy content was identical and macronutrient composition was virtually identical between treatments-Fabuless containing test drinks (both processed and unprocessed): 266 kcal, 15.2 g protein (23% of delivered energy), 5.7 g fat (19% of delivered energy) and 38 g carbohydrate per serving; control test drinks: 268 kcal, 15.4 g protein (23% of delivered energy), 5.8 g fat (19% of delivered energy) and 39 g carbohydrate per serving. The test drinks were manufactured by International Food Network Ltd, Reading, UK.
Lunch. This ad lib meal consisted of (1) a large plate of standardized cheese sandwiches made of 10 slices of bread with five slices of medium-strength Cheddar cheese (24 g each). Sandwiches were cut to the size of the cheese slice. Each slice of bread was buttered with 3.0 g of margarine and sandwiches were divided into four equal smaller triangles before serving; (2) a smaller plate containing one pack (200 g) of 'custard-creams' biscuits; (3) a clear jug containing 1 l of non-carbonated water. The total energy content of the meal served was 10 531 kJ.
Dinner. This ad lib meal consisted of (1) a large plate containing around 1000 g bacon and leek pasta bake, prepared immediately before serving in a microwave oven according to the food manufacturer's guidelines; (2) a bowl containing 450 g strawberry yoghurt; and (3) a clear jug containing 1 l of non-carbonated water. The total energy content of the meal served was 8844 kJ.
Measures
The measures taken for statistical analysis were as follows: 1. Energy intake (kJ) at lunch, dinner, and lunch and dinner combined. 2. Food intake (g) at lunch, dinner, and lunch and dinner combined. 3. Appetite and mood-related feelings (100-point VAS), measuring 'Full', 'Hungry', 'Appetite for a snack', 'Thirsty', 'Satiated', 'How much you could eat', 'Energetic' and 'Drained'. 4. Physical symptoms experienced in the past hour (4-point scale, labelled as 'not at all', 'mild', 'moderate' and 'severe'). 5. Pleasantness ratings for various sensory aspects of the yoghurt-based meal replacement drink (100 mm paper VAS).
Appetite, mood and physical symptom ratings were recorded electronically on a Palm Zire PDA.
Statistical analysis
Statistical analysis was carried out using SAS 8.0 (Cary, NC, USA). As there were negligible differences between analysis No efficacy of Fabuless HJ Smit et al of variance and analysis of covariance outcomes, estimated means adjusted for baseline differences were not calculated and overall treatment effects for the VAS and food intake data were eventually analysed using analysis of variance with subject, treatment and period as factors. P-values o0.05 were considered statistically significant. Next, 'active' treatments were compared against control using Fisher's least significant difference test as reported in the Results. The comparisons (one-tailed t-tests) were corrected for multiple comparisons by using a pooled error term. Frequencies of physical symptoms were compared between treatments using w 2 .
Results
Participant characteristics
In total, 24 participants (16 female, eight male) were recruited into the study, with an average age of 23.3 years ( ± 5.3; range 18-43), mean BMI of 22.4 kg/m 2 ( ± 3.8; range
18.1-37.0) and DEBQ-restraint scores of 2.1 ( ± 0.6; range 1.2-3.2). Age did not differ significantly between the two sexes, though females showed a predictable trend for higher scores on BMI and dietary restraint (DEBQ restraint scale) compared with males. Baseline characteristics are presented in Table 1 .
Pleasantness and mood ratings, and physical symptoms
No differences in overall product pleasantness (taste, aroma, flavour), mood, or adverse physical symptoms were observed between treatments (P40.1).
Appetite and satiety ratings
No treatment effects were found for any appetite measures over various time periods using area-under-curve data (P40.5). Additionally, sporadic effects at individual time points, usually immediately pre-meal, are not confirmed by other, related measures (see Figure 2 ).
Food and energy intake
Results for food intake at lunch and dinner are shown in Table 2 .
Lunch. Neither energy intake (kJ) nor food intake (g) at lunch were significantly affected by either of the Fabuless test drinks when compared with control (P40.2).
Dinner. Energy intake at dinner was significantly lower (pasta alone: t(42) ¼ 2.79; P ¼ 0.004; dinner total: t(42) ¼ 2.46; P ¼ 0.009) following the unprocessed Fabuless test drink compared with control, but not following processed Fabuless vs control (P40.1).
Accordingly, food intake at dinner was also reduced by the unprocessed Fabuless test drink compared with control (t(42) ¼ 211; P ¼ 0.021). In contrast, neither energy nor food intake at dinner was reduced by the processed Fabuless test drink compared with control (P ¼ 0.2). The results were similar for total (lunch þ dinner) energy intake.
Discussion
The present study found that processing of Fabuless in a yoghurt beverage eliminated the modest, but statistically significant effects on food intake observed when the ingredient was added at the end of manufacture. The significant effects of the unprocessed ingredient were found at 8 h after the treatment consumption (dinner) and generally not at 4 h post-treatment (lunch).
An ingredient that reliably leads to significant and meaningful reductions in energy intake could be highly beneficial in a weight management context and, therefore, highly desirable to consumers who want to achieve an ideal weight. Fabuless is marketed as such an ingredient on the basis of data obtained from an initial series of studies reported by Burns et al. (2000 Burns et al. ( , 2001 Burns et al. ( , 2002 , which suggested that Fabuless could reduce 24-h energy intake by up to an impressive 30%. However, subsequent studies by the same and other groups (Logan et al., 2006; Diepvens et al., 2008) have not replicated these initial results, and the nature of the ingredient (a structured emulsion) suggests that it could be sensitive to common processes used in food production.
The sample size and sensitivity of measures in the current study were appropriate for this type of study design (Flint et al., 2000; Gregersen et al., 2008) . However, the magnitude of food intake effects for unprocessed Fabuless seen here (B10% energy intake reduction compared with control) was much less than that in the Burns et al. (2000 Burns et al. ( , 2001 Burns et al. ( , 2002 studies (average ¼ 23% reduction). The reasons for this difference are not entirely clear. However, compared with other studies, the magnitude of the effect reported by Burns et al. is unusually large, especially considering that anorectic drugs have achieved similar magnitudes of effect. For example, Rogers and Blundell (1979) found that fenfluramine reduced food intake by 26%, whereas Rolls et al. (1998) showed a maximum energy intake reductive effect of 26%, but only after a 14-day sibutramine course.
Our findings may partially replicate results from Burns et al. (2000 Burns et al. ( , 2001 Burns et al. ( , 2002 for the unprocessed Fabuless used here, but show that thermal and shear processing eliminates the functionality of this food ingredient. Indeed, high-shear mixing and homogenizing may destabilize emulsified structures by means of coalescence or flocculation of the dispersed phase, whilst subsequent pasteurizing may provide an additional destabilizing risk through protein denaturization (McClements, 2005) . Note that it is unclear exactly what type or level of processing and storage of Fabuless was applied in the 'Burns' trials. Commercial products containing Fabuless will typically be exposed to the same or other basic food-manufacturing processes as used in the 'processed' treatments in our study. Nevertheless, micrographic images of the products used in this trial (not shown here) indicate a finer dispersion of the lipid fraction in Fabuless after processing. However, we are not aware of any structural assessment of Fabuless that definitively predicts the integrity of its functional efficacy. Without such a test, it is difficult to predict when functionality is retained, other than by empirical clinical testing. Therefore, evidence for the effectiveness of Fabuless is only relevant if there is explicit evidence that functionality (and not just a particular structure) is retained in products when processed, stored and prepared as relevant to the market product. Although it is certainly possible that different or milder processes may have less effects on efficacy, the effects and limits of process sensitivity need to be shown.
One remarkable aspect of the study presented in this paper is the general lack of effects on self-reported appetite and satiety measures. Methodologically, the VAS measures were sound, as clear effects were found in subsequent work using the same participants, measures and instructions (not related to the current hypothesis and/or Fabuless; data not published). Note, however, that Burns et al. (2002) also reported no effects of Fabuless on appetite-related ratings, regardless of test conditions.
The proposed mechanism in support of the claims for Fabuless has been termed the 'ileal brake': When fat is presented to the distal ileum, it elicits a strong satiety response (for example, Lin et al., 1996) , an inhibition of upper gastrointestinal functions elicited mainly by the release of glucagon-like peptide-1 in response to the presence of unabsorbed nutrients in the ileum (for example, Giralt and Vergara, 1999; Näslund et al., 1999; Brubaker et al., 2002; Delgado-Aros et al., 2002) . Even the infusion of 3 g fat into the ileum delayed small intestinal transit (Symersky et al., 2004) . Although it is unclear how much undigested fat of the 5-g fat in the Fabuless conditions reaches the ileum, it is unlikely to be more than 3 g. Moreover, Fabuless is generally added in amounts less than 5 g per daily intake equivalent. Finally, although fat is the most commonly researched macronutrient in this respect, also undigested carbohydrates and proteins can induce the ileal brake mechanism (Maljaars et al., 2008) , and the mechanism underlying the ileal brake effect is yet to be established (Maljaars et al., 2008) . Note also that there is currently no direct evidence in support of the proposed 'targeted delivery' mechanism of Fabuless (that is, how the emulsion passes through the stomach into the ileum without being affected). Although a recent report by Haenni et al. (2009) claims that Fabuless leads to a 45 min longer oro-caecal transit time, this seems incongruent with the fact that the only significant effects observed in our study were at 8 h post-ingestion. In addition, Haenni et al. (2009) used an unconventional method of calculating oro-caecal transit time (using group mean plasma marker values instead of individual marker appearance times; for example, Staniforth (1989) and Peh and Yuen (1996) ), which may have exaggerated individual outlier responses. In summary, the results of this study show a modest, statistically significant effect only of unprocessed Fabuless on food and energy intake, whereas no significant effects were observed when the active ingredient was added prior to homogenization and pasteurization. These findings replicate to some extent the earlier demonstrations of inhibitory effects of Fabuless on food and energy intake (Burns et al., 2000 (Burns et al., , 2001 (Burns et al., , 2002 , although the magnitudes of effects were much smaller here and perhaps more realistic. Moreover, no effects of Fabuless on appetite-related ratings were found. Given the clear loss of efficacy when Fabuless is subjected to normal food processing, functionality after actual processing and storage conditions must be empirically confirmed for any product making claims based on this ingredient.
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